Equinor ASA
29.1.2021 08:01:56 CET | Globenewswire | Press release
Equinor (OSE: EQNR, NYSE: EQNR) has decided to write down the book value of its Tanzania LNG project (TLNG) on the company’s balance sheet by 982million USD. This will be reflected in adjusted earnings for EPI division in fourth quarter 2020 results to be reported on 10 February 2021.
While progress has been made in recent years on the commercial framework for TLNG, overall project economics have not yet improved sufficiently to justify keeping it on the balance sheet. The TLNG project has an anticipated breakeven price well above the portfolio average for Equinor and is, at this time, not competitive within this portfolio. Equinor will continue to engage with the Government of Tanzania in negotiations on a commercial, fiscal and legal framework that may provide a viable business case for TLNG in the future.
Equinor maintains an attractive portfolio of project development opportunities in oil and gas as well as renewables. This portfolio requires strict prioritization, ensuring capital is allocated towards projects yielding the most competitive returns. As shown at the Capital Markets Update in February last year, Equinor’s oil and gas projects with expected start-up by 2026 have an average breakeven below $35/bbl based on today’s estimates. Similar for non-sanctioned oil and gas projects with expected start-up within this decade, the average breakeven is below $40/bbl.
Equinor has been present in Tanzania since 2007 when the company signed a Production Sharing Agreement (PSA) with the Tanzania Petroleum Development Corporation (TPDC). Equinor is the operator with a 65% participating interest, along with ExxonMobil’s working interest of 35%. TPDC has the right to participate with a 10% interest. Equinor made nine gas discoveries in Block 2 offshore Tanzania with estimated volumes of 20 Tcf of gas in place.
Contacts
Investor relations:
Peter Hutton
Senior vice president Investor Relations
+44 7881 918 792 (mobile)
Media:
Erik Haaland
Manager Media Relations
+47 954 21 770 (mobile)
This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Unibail-Rodamco-Westfield SE25.3.2026 17:45:00 CET | Press release
Availability of the 2025 Universal Registration Document, terms for holding the Combined General Meeting of Unibail-Rodamco-Westfield SE on May 6, 2026, and availability of the explanatory documentation
Sanoma Corp25.3.2026 17:30:00 CET | Press release
SANOMA CORPORATION: ACQUISITION OF OWN SHARES 25 March 2026
Io Therapeutics, Inc.25.3.2026 17:15:00 CET | Press release
Io Therapeutics, Inc. announces publication in Scientific Reports – Nature, of studies showing synergistic efficacy of its RXR agonist IRX4204 with the standard of care drug lenalidomide against multiple myeloma.
DFDS A/S25.3.2026 17:01:09 CET | Press release
DFDS A/S – SUMMARY OF ANNUAL GENERAL MEETING
DFDS A/S25.3.2026 17:01:09 CET | Pressemeddelelse
DFDS A/S – FORLØB AF ORDINÆR GENERALFORSAMLING
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
